📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 12:17
72 analysed today
FollowTelegram
72
Today
150,511
All-time analysed
43,115
Positive
6,694
Negative
91,943
Neutral
8,691
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Relic Technologies Reports Q1 FY27 Consolidated Net Loss of ₹1.03 Cr; Revenue Drops 72% YoY
Relic Technologies reported a consolidated net loss of ₹1.03 Cr for Q1 FY27, an improvement from the ₹3.68 Cr loss in Q1 FY26. Consolidated revenue from operations fell sharply by 72% YoY to ₹35.49 Lakhs from ₹1.28 Cr. On a standalone basis, the company turned profitable with a net profit of ₹21.47 Lakhs, aided by ₹43 Lakhs in other income. A significant development is the commencement of a new trading vertical in pharmaceuticals and wellness products, which contributed ₹21.15 Lakhs to standalone revenue.
Confidence: HIGH
What changedThe company has officially commenced revenue-generating trading activities in pharmaceuticals, wellness, and healthcare products.
Why it mattersWith a TTM revenue of only ₹3 Cr and persistent losses, the success of this new trading vertical is critical for the company's financial turnaround and survival.
Consolidated Revenue (Q1 FY27): ₹35.49 LakhsConsolidated Net Loss (Q1 FY27): ₹102.75 LakhsStandalone Trading Revenue: ₹21.15 LakhsConsolidated Revenue vs TTM Revenue: ~11.8%Consolidated Employee Expenses: ₹78.79 Lakhs
📅 Short termThe significant drop in YoY consolidated revenue and continued losses are likely to keep the stock under pressure in the near term.
📈 Long termThe long-term outlook depends entirely on the company's ability to scale its new pharma trading business and achieve consolidated profitability, which remains unproven.
⚠ Risk flags
- High employee costs relative to total income
- Significant YoY revenue decline
- Continued consolidated losses
- Small scale of operations
Key Highlights
Consolidated Net Loss narrowed to ₹1.03 Cr compared to a loss of ₹3.68 Cr in the same quarter last year.
Consolidated Revenue from operations declined 72.3% YoY to ₹35.49 Lakhs.
Standalone operations reported a Net Profit of ₹21.47 Lakhs, primarily driven by ₹43 Lakhs in Other Income.
Commenced new trading activities in pharmaceuticals and wellness products during the quarter.
Consolidated employee benefit expenses remain high at ₹78.79 Lakhs, exceeding total income of ₹57.86 Lakhs.
👀 What to Watch
Investors should monitor the scale-up of the new pharmaceutical trading business and whether it can generate enough margin to cover the high consolidated employee costs.
Relic Technologies Q1 FY27: Consolidated Net Loss Narrows to ₹1.03 Cr; Pharma Trading Commences
Relic Technologies reported a consolidated net loss of ₹1.03 Cr for the quarter ended June 30, 2026, showing improvement from a loss of ₹3.68 Cr in the same period last year. Consolidated revenue from operations fell significantly by 72% YoY to ₹35.49 Lakhs. On a standalone basis, the company turned a profit of ₹21.47 Lakhs, largely supported by ₹43 Lakhs in other income and the commencement of a new pharmaceutical and wellness product trading business. However, its subsidiaries (Relic Pharma and Truhealthy Wellness) remain a major drag, contributing a combined loss of ₹1.24 Cr.
Confidence: HIGH
What changedThe company has officially commenced revenue generation from a new trading segment in pharmaceuticals and wellness products while narrowing its consolidated losses.
Why it mattersFor a micro-cap company with a market cap of ₹44 Cr and negative TTM margins, the pivot to pharma trading represents a critical attempt to establish a sustainable revenue model, though subsidiary losses remain a structural concern.
Consolidated Net Loss (Q1): ₹1.03 CrConsolidated Revenue (Q1): ₹35.49 LakhsStandalone Other Income: ₹43.00 LakhsSubsidiary Net Loss: ₹1.24 CrQ1 Revenue vs TTM Revenue: ~11.8%
📅 Short termThe narrowing of losses and standalone profitability might provide some support, but the sharp drop in consolidated revenue is a concern for the next few weeks.
📈 Long termThe long-term outlook depends entirely on the company's ability to scale its new pharma trading business and turn around or divest its loss-making subsidiaries.
⚠ Risk flags
- Significant subsidiary losses exceeding consolidated revenue
- High reliance on Other Income for standalone profitability
- Sharp YoY decline in consolidated revenue
Key Highlights
Consolidated Net Loss narrowed to ₹102.75 Lakhs from ₹368.32 Lakhs in the year-ago quarter.
Consolidated Revenue from Operations declined to ₹35.49 Lakhs from ₹128.15 Lakhs YoY.
Standalone Net Profit rose to ₹21.47 Lakhs, aided by ₹43 Lakhs in Other Income.
Subsidiaries reported a combined net loss of ₹124.22 Lakhs on a small revenue base of ₹14.34 Lakhs.
Commenced new revenue stream from trading in pharmaceuticals, nutraceuticals, and healthcare products.
👀 What to Watch
Investors should monitor the scalability of the newly launched pharmaceutical trading business and whether it can offset the persistent losses in the subsidiary companies.
